Bioneer A/S

Bioneer, founded in 1982, is a trusted R&D partner to biotech and pharma, with deep expertise in CNS research. As an R&D driven CRO/CDMO, we support discovery, development, and manufacture of early CNS drug candidates and recombinant proteins. Our CNS capabilities include CRISPR gene editing, advanced human neural and disease models, and a synuclein (a SYN) assays to accelerate mechanistic insights and target engagement for neurodegenerative programs. Read more about our CNS services: In Vitro Modelling – Bioneer